NCT06792825 2025-08-12HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZLMasonic Cancer Center, University of MinnesotaPhase 2 Recruiting65 enrolled